Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating safety, tolerability, pharmacokinetics, and efficacy of 180 mg subcutaneous risperidone following 6 mg oral risperidone in schizophreni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• RISPERIDONE (RISPERIDONE)

Snippet

Sponsor: Indivior Inc. | Conditions: Schizophrenia | Phase 4 | Status: COMPLETED | Results posted: 2021-07-07